Polyarthritis in primary Sjögren’s syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up

Clinical Rheumatology

Volumn 35, Issue 3, 2016, Pages 649-655

  ter Borg, E J ^a   Kelder, J C ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Hypergammaglobulinaemia; Polyarthritis; Primary Sj gren s syndrome; Systemic auto antibodies

Indexed keywords

ANTI SJOGREN SYNDROME RELATED ANTIGEN A; ANTI SJOGREN SYNDROME TYPE B; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M RHEUMATOID FACTOR; METHOTREXATE; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INVESTIGATIVE PROCEDURES; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; METACARPOPHALANGEAL JOINT; METATARSOPHALANGEAL JOINT; MORNING STIFFNESS; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROXIMAL INTERPHALANGEAL JOINT; RHEUMATOID ARTHRITIS; SEROLOGY; SJOEGREN SYNDROME; WRIST; AGED; ARTHRITIS; BLOOD; CELL PROLIFERATION; COMPLICATION; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PHYSIOLOGY; SJOGREN'S SYNDROME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS; AUTOANTIBODIES; B-LYMPHOCYTES; CELL PROLIFERATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; SJOGREN'S SYNDROME;

EID: 84960338072     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3175-3     Document Type: Article

References (15)

1. Hansen A, Lipsky PE, Dörner T (2003) New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumatol 15:563–570
2. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
3. ter Borg EJ, Risselada AP, Kelder JC (2011) Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren’s syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum 40:547–551
4. Fauchais A-L, Quattara B, Gondran G, Lalloue F, Petit D, Lambert M et al (2010) Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients. Rheumatology 49:1164–1172
5. ter Borg EJ, Kelder JC (2014) Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjögren’s syndrome and widespread pain: evidence for a relatively benign subset. Clin Exp Rheumatol 32(3):349–353
6. Gottenberg J-E, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Autocoutourier F, Goetz J et al (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in primary Sjögren’s syndrome. Ann Rheum Dis 64:114–117
7. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Pino-Montes J et al (2008) Primary Sjögren syndrome in Spain. Clinical and immunological expression in 1010 patients. Medicine 87:210–219
8. Baldini C, Pepe P, Quartuccion L, Priori R, Bartolini E, Aluno A et al (2014) Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 53:839–844
9. Pertovaara M, Pukkala E, Laippala P, Miettinen P, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467–472
10. Castro-Poltronieri A, Alarcon-Segovia D (1983) Articular manifestations of primary Sjögren’s syndrome. J Rheumatol 10:485–488
11. Lazarus MN, Isenberg DA (2005) Development of additional autoimmune diseases in a population with primary Sjögren’s syndrome. Ann Rheum Dis 64:1062–1064
12. Mohammed K, Pope J, le Riche N, Brintnell W, Cairns E, Coles R et al (2009) Association of severe inflammatory polyarthritis in primary Sjögren’s syndrome: clinical, serological and HLA analysis. J Rheumatol 36:1937–1942
13. Khan O, Carsons S (2012) Occurrence of rheumatoid arthritis requiring oral and/or biological disease-modifying anti-rheumatic drug therapy following a diagnosis of primary Sjögren’s syndrome. J Clin Rheumatol 18:356–358
14. Iwamoto N, Kawakami A, Tamai M, Fujikawa K, Arima AT et al (2009) Determination of the subset of Sjögren’s syndrome with articular manifestations by anti-cyclic citrullinated peptide antibodies. J Rheumatol 36:113–115
15. Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dorner et al (2015) Characterisation of systemic disease in primary Sjögren’s syndrome: EULAR Task Force recommendations for articular, cutaneous and renal involvements. Rheumatology 54:2230–2238